New sleepiness drug ORX142 enters first human tests
NCT ID NCT07082829
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called ORX142 in healthy adults and older adults to see if it is safe and how the body processes it. The study also looks at how food affects the drug and whether it can improve alertness in people who are sleep-deprived. About 208 participants will take either ORX142 or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ORX142 tablets
What this could lead to
If successful, this could lead to a new treatment option for people with excessive daytime sleepiness.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if ORX142 will actually help with sleepiness. The study is small and in healthy volunteers, not patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXCESSIVE DAYTIME SLEEPINESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site #1
RECRUITINGLincoln, Nebraska, 68502, United States
-
Site #2
RECRUITINGEatontown, New Jersey, 07724, United States
-
Site #3
RECRUITINGNew York, New York, 10019, United States